A Severe Refractory Anaemia and Fever of Unknow Origin: Human Parvovirus B19 Reactivation

  • Joaquín Escobar-Sevilla Hospital Universitario Virgen de las Nieves, Granada, Spain
  • Antonio Bustos Merlo Hospital Universitario Virgen de las Nieves, Granada, Spain
  • Juan Diego Mediavilla Garcia Hospital Universitario Virgen de las Nieves, Granada, Spain
  • Carmen Garcia Martínez Hospital Universitario Virgen de las Nieves, Granada, Spain

Keywords

Human parvovirus B19, pure red cell aplasia, viral reactivation

Abstract

Reactivation of human parvovirus B19 is exceptional and characteristic of immunosuppression, with anaemia being the predominant manifestation although pancytopenia and thrombotic microangiopathy may also occur. We describe a patient with a history of diffuse large B-cell lymphoma with pure erythrocyte aplasia due to reactivation of parvovirus B19, who was treated with corticosteroids and immunoglobulins.

VIEW THE ENTIRE ARTICLE

References

  • Eid AJ, Brown RA, Patel R, Razonable RR. Parvovirus B19 infection after transplantation: a review of 98 cases. Clin Infect Dis 2006;43:40–48.

  • Eid AJ, Chen SF, AST Infectious Diseases Community of Practice. Human parvovirus B19 in solid organ transplantation. Am J Transplant 2013;13(Suppl 4):201–205.

  • Sterpu R, Ichou H, Mahé EI, Mortier E. Reactivation of parvovirus B19 infection in an HIV-infected woman. Rev Med Interne 2014;35(6):396–398.

  • García-Muñoz R, Galar A, Moreno C, Rodríguez-Otero P, Panizo-Morgado E, Ponz-Sarvisê M, et al. Parvovirus B19 acute infection and a reactivation of cytomegalovirus and herpesvirus 6 in a chronic myeloid leukemia patient during treatment with dasatinib (BMS-354825). Leuk Lymphoma 2007;48(12):2461–2464.

  • Klepfish A, Rachmilevitch E, Schattner A. Parvivovirus B19 reactivation presenting as neutropenia after rituximab treatment. Eur J Intern Med 2006;17(7):505–507.

  • Eid AJ, Ardura MI. Human parvovirus B19 in solid organ transplantation: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 2019;33(9):e13535.

  • Baek CH, Kim H, Yang WS, Han DJ, Park SK. Risk factors and long-term outcomes of parvovirus B19 infection in kidney transplant patients. Transpl Infect Dis 2017;19:e12754.

  • Gosset C, Viglietti D, Hue K, Antoine C, Glotz D, Pillebout E. How many times can parvovirus B19-related anemia recur in solid organ transplant recipients? Transpl Infect Dis 2012;14:E64–E70.

  • Ki CS, Kim IS, Kim JW, Lee NY, Kim SH, Lee KW, et al. Incidence and clinical significance of human parvovirus B19 infection in kidney transplant recipients. Clin Transplant 2005;19(6):751–755.

  • Park JB, Kim DJ, Woo SY, Choi GS, Chun JM, Jung GO, et al. Clinical implications of quantitative real time-polymerase chain reaction of parvovirus B19 in kidney transplant recipients - a prospective study. Transplant Int 2009;22(4):455–462.

  • Hai AHP, Diem HT, Cuong NT. Parvovirus B19-associated anemia in kidney transplant recipients: a single-center experience. Transplant Proc 2019;51(8):2693–2696.

  • Gama BE, Emmel VE, Oliveira-Silva M, Gutiyama LM, Arcuri L, Colares M, et al. Parvovirus B19 in the context of hematopoietic stem cell transplantation: evaluating cell donors and recipients. Transplant Direct 2017;3(11):e217.

  • Inazawa N, Hori T, Noijma M. Virus reactivation after autologous hematopoietic stem cell transplantation detected by multiplex PCR assay. J Med Virol 2017;89(2):358–362.

  • Zolnourian ZR, Curran MD, Rima BK, Coyle PV, O'Neill HJ, Middleton D. Parvovirus B19 in kidney transplant patients. Transplantation 2000;69(10):2198–2202.

  • Porigaux R, Vuiblet V, Barbe C. Frequent occurrence of parvovirus B19 DNAemia in the first year after kidney transplantation. J Med Virol 2013;85(6):1115–1121.

  • Plentz A, Wurdinger M, Kudlich M, Modrow S. Low-level DNAemia of parvovirus B19 (genotypes 1-3) in adult transplant recipients is not associated with anaemia. J Clin Virol 2013;58:443–448.

  • Park JB, Kim DJ, Woo SY, Choi GS, Chun JM, Jung GO, et al. Clinical implications of quantitative real time-polymerase chain reaction of parvovirus B19 in kidney transplant recipients - a prospective study. Transplant Int 2009;22(4):455–462.

  • Lefrère JJ, Servant-Delmas A, Candotti D, Mariotti M, Thomas I, Brossard Y, et al. Persistent B19 infection in immunocompetent individuals: implications for transfusion safety. Blood 2005;106(8):2890–2895.

  • Young SN, Brown KE. Parvovirus B19. N Engl J Med 2004;350:586–597.

  • Kerr JR. Parvovirus B19 infection. Eur J Clin Microbiol Infect Dis 1999;15:10–29.
  • Published: 2020-06-25

    Issue: Vol 7 No 9 (view)

    Section: Articles

    How to cite:
    1.
    Escobar-Sevilla J, Bustos Merlo A, Mediavilla Garcia JD, Garcia Martínez C. A Severe Refractory Anaemia and Fever of Unknow Origin: Human Parvovirus B19 Reactivation. EJCRIM [Internet]. 2020Jun.25 [cited 2020Oct.24];7(9). Available from: https://www.ejcrim.com/index.php/EJCRIM/article/view/1596